Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker CADL
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Jul 27, 2026 | SCHEDULE 13G | CADL Candel Therapeutics, Inc. | BlackRock, Inc. | 4.83M | 6.6% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | CADL Candel Therapeutics, Inc. | Roderick Wong | 6.42M | 8.8% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | CADL Candel Therapeutics, Inc. | RTW Investments, LP | 6.42M | 8.8% | SCHEDULE 13G ↗ |
| Apr 27, 2026 | SCHEDULE 13G/A (amended) | CADL Candel Therapeutics, Inc. | BlackRock, Inc. | 3.08M | 4.2% | SCHEDULE 13G/A ↗ |
| Mar 18, 2026 | SCHEDULE 13D/A (amended) | CADL Candel Therapeutics, Inc. | BKB Growth Investments, LLC | 1.30M | 1.8% | SCHEDULE 13D/A ↗ |
| Mar 18, 2026 | SCHEDULE 13D/A (amended) | CADL Candel Therapeutics, Inc. | The Paul B. Manning Revocable Trust dated May 10, 2000 | 2.76M | 3.8% | SCHEDULE 13D/A ↗ |
| Mar 18, 2026 | SCHEDULE 13D/A (amended) | CADL Candel Therapeutics, Inc. | Paul B Manning | 5.79M | 7.9% | SCHEDULE 13D/A ↗ |
| Jan 21, 2026 | SCHEDULE 13G | CADL Candel Therapeutics, Inc. | BlackRock, Inc. | 2.86M | 5.2% | SCHEDULE 13G ↗ |
| Jun 30, 2025 | SCHEDULE 13G | CADL Candel Therapeutics, Inc. | Anders Hove | 2.58M | 5.2% | SCHEDULE 13G ↗ |
| Jun 30, 2025 | SCHEDULE 13G | CADL Candel Therapeutics, Inc. | Acorn Capital Advisors GP2, LLC | 1.50M | 3.0% | SCHEDULE 13G ↗ |
| Jun 30, 2025 | SCHEDULE 13G | CADL Candel Therapeutics, Inc. | Acorn Capital Advisors GP, LLC | 1.08M | 2.2% | SCHEDULE 13G ↗ |
| Jun 30, 2025 | SCHEDULE 13G | CADL Candel Therapeutics, Inc. | Acorn Bioventures 2, L.P. | 1.50M | 3.0% | SCHEDULE 13G ↗ |
| Jun 30, 2025 | SCHEDULE 13G | CADL Candel Therapeutics, Inc. | Acorn Bioventures, L.P. | 1.08M | 2.2% | SCHEDULE 13G ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | CADL Candel Therapeutics, Inc. | Felix J. Baker | 2.46M | 5.0% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | CADL Candel Therapeutics, Inc. | Julian C. Baker | 2.46M | 5.0% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | CADL Candel Therapeutics, Inc. | Baker Bros. Advisors (GP) LLC | 2.46M | 5.0% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | CADL Candel Therapeutics, Inc. | Baker Bros. Advisors LP | 2.46M | 5.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | CADL Candel Therapeutics, Inc. | Michael P. Rubin | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | CADL Candel Therapeutics, Inc. | Northpond Ventures II GP, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | CADL Candel Therapeutics, Inc. | Northpond Ventures II, LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | CADL Candel Therapeutics, Inc. | Northpond Ventures GP, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | CADL Candel Therapeutics, Inc. | Northpond Ventures, LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G | CADL Candel Therapeutics, Inc. | Felix J. Baker | 2.98M | 6.8% | SCHEDULE 13G ↗ |
| Feb 14, 2025 | SCHEDULE 13G | CADL Candel Therapeutics, Inc. | Julian C. Baker | 2.98M | 6.8% | SCHEDULE 13G ↗ |
| Feb 14, 2025 | SCHEDULE 13G | CADL Candel Therapeutics, Inc. | Baker Bros. Advisors (GP) LLC | 2.98M | 6.8% | SCHEDULE 13G ↗ |
| Feb 14, 2025 | SCHEDULE 13G | CADL Candel Therapeutics, Inc. | Baker Bros. Advisors LP | 2.98M | 6.8% | SCHEDULE 13G ↗ |
| Feb 7, 2025 | SCHEDULE 13G/A (amended) | CADL Candel Therapeutics, Inc. | Heights Capital Management, Inc. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 7, 2025 | SCHEDULE 13G/A (amended) | CADL Candel Therapeutics, Inc. | CVI Investments, Inc. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 7, 2025 | SCHEDULE 13G/A (amended) | CADL Candel Therapeutics, Inc. | Abigail P. Johnson | 6.32M | 15.0% | SCHEDULE 13G/A ↗ |
| Feb 7, 2025 | SCHEDULE 13G/A (amended) | CADL Candel Therapeutics, Inc. | FMR LLC | 6.32M | 15.0% | SCHEDULE 13G/A ↗ |
| Feb 7, 2025 | SCHEDULE 13G | CADL Candel Therapeutics, Inc. | Abigail P. Johnson | 3.92M | 9.3% | SCHEDULE 13G ↗ |
| Feb 7, 2025 | SCHEDULE 13G | CADL Candel Therapeutics, Inc. | FMR LLC | 3.92M | 9.3% | SCHEDULE 13G ↗ |
32 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:42 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances